HJ SCIENCE-B (06132) commenced trading on its first day of listing. According to the company's announcement, shares were priced at HK$81.8 each. A total of 13.6 million shares were issued, with a board lot size of 100 shares. The net proceeds from the offering amounted to approximately HK$1.019 billion.

As of the latest update, the stock was trading flat at HK$81.8, with a turnover of HK$389 million.

Information from the prospectus indicates that HJ SCIENCE-B (ASX: 06132) is a clinical-stage biotechnology company founded in 2017 by a team of industry experts dedicated to developing therapies for autoimmune, metabolic, and oncology diseases. The company possesses three core products: HJ787, HJ178, and HJ891. All are self-developed small-molecule drugs classified by the National Medical Products Administration as Category 1 innovative drugs.

To date, the company has not received approval for the commercial sale of any products and has not generated any revenue from product sales.

HJ SCIENCE-B has established a development platform for small-molecule drugs, covering the entire process from drug design, efficient synthesis, screening and evaluation, pharmacological studies, and comprehensive CMC research to clinical strategy and operations, as well as translational medicine. This platform integrates computational simulation with experimental drug design and screening, targeted and rapid drug-likeness assessment, and efficient CMC development and clinical studies.

Utilizing this integrated approach, the company has advanced multiple drug candidates with significant differentiation across various therapeutic areas.